Presentation of Caroline Robert (Abstract LBA40):
''In the COMBI-v study of 704 patients with BRAF V600E/K-mutant melanoma, results of an updated 3-year analysis revealed an increased rate of overall survival with first-line dabrafenib
plus trametinib compared with vemurafenib (45% versus 32%, respectively) with no apparent increase in toxicities.
Combination dabrafenib/trametinib shows also a median overall survival of 26,1 months on combination versus 17, 2 months on vemurafenib.
Combi-v compared dabrafenib/trametinib with vemurafenib alone while Combi d compared the dabrafenib/trametinib with dabrafenib alone. Both trials demonstrated the superiority of combination (see figure bellow), thus combination Dabrafenib /Trametinib is (highly) recommended as first line therapy in melanoma for Braf positive patients.